Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.

Levobupivacaine better as monotherapy than with lidocaine

21 Sep 2017

Paravertebral block (PVB) induced by levobupivacaine alone results in a longer time-to-block onset and reduced haemodynamic disruptions in breast cancer patients undergoing quadrantectomy compared with levobupivacaine combined with lidocaine, a new study has found.

Investigators randomized 85 breast cancer patients scheduled for surgical quadrantectomy to receive either levobupivacaine and lidocaine (LLG group; n=43) or levobupivacaine alone (LG group; n=42) for thoracic PVB. Those with coagulation and uncontrolled psychiatric disorders were excluded.

Analgesic and haemodynamic outcomes were observed, primary of which were the time-to-block onset, duration of analgesia and stroke volume variation (SVV) in the first 60 minutes after PVB.

SVV during the first hour after induction of PVB was significantly higher in the LLG group (least squares mean difference [MD], 4.33; 95 percent CI, 3.80 to 4.88; p<0.0001) than in the LG group, with the bulk of the difference occurring in the first 35 minutes.

While there were no significant differences in the secondary haemodynamic measures of mean arterial pressure, heart rate and cardiac output, these parameters, including SVV, showed significant interactions with time (p<0.001 for all).

The LLG group also showed significantly shorter time-to-block onset (23.0 vs 37.0 minutes; p<0.001) and duration of analgesia (385.0 vs 490.0 minutes; p=0.006) compared with the LG group. In contrast, the secondary outcome of intraoperative crystalloid infusion was significantly higher in the LLG group (1,150 vs 600 mL; p<0.001).

“The results of this trial showed that, for PVB, the administration of a single local anaesthetic levobupivacaine in comparison with a solution of two different local anaesthetics, levobupivacaine and lidocaine, had a more favourable haemodynamic and analgesic profile,” concluded the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.